Cadex Genomics develops molecular diagnostic tests to guide cancer treatment using liquid-based technology to provide personalized insight into therapy response
At Cadex Genomics, we are interrogating a late-stage cancer patient's blood to determine if a tumor is growing early in a line of therapy and identify non-effective therapy in 12-21 days after starting a cycle of therapy versus waiting 8-12 weeks. issuu.com/mdnext/docs/md-nex…
We're excited to have a new channel with which to showcase the entrepreneurs, physicians, dentists, investors & Industry stakeholders advancing healthcare innovation day in and day out.
Please join Cadex Genomics and AngelMD Capital at a webinar on Wednesday, August 17th to learn more about real-time therapy monitoring for cancer patients. Save your seat: docs.google.com/forms/d/e/1F…
Cadex Genomics founders Bill Haack and Greg Schafer talk about real-time cancer therapy monitoring on the MedTech Trends podcast.
youtube.com/watch?v=4lvStFvA…
C&M intellectual property lawyers wrote about the recent Illumina v. Ariosa Diagnostics case in @IAM_Magazine, unpacking the news for diagnostics innovators. Read more: CVSoci.al/oQGn9OAp
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper | Nature Reviews Clinical Oncology. Notes the opportunities and gaps in knowledge. @VanMorrisMD and Arvind Dasari @MDAndersonNews nature.com/articles/s41571-0…
"...Diagnostics have been really taken for granted Its been viewed as a commodity for the industry, an afterthought. It isn’t valued properly in the whole healthcare continuum. It isn’t paid for properly. I think that’s changing now..."
medcitynews.com/2020/05/sect…
#ICYMI: Gayle Benson, a favorite Saint, will invest $50 million in Gulf South startups with a new venture fund. A touchdown for economic growth and small business owners in our region.
nola.com/news/article_fd90e0…